Rs351855

From SNPedia
Jump to: navigation, search

Orientationminus
is asnp
is mentioned by
dbSNPrs351855
PheGenIrs351855
nextbiors351855
hapmaprs351855
1000 genomesrs351855
hgdprs351855
ensemblrs351855
gopubmedrs351855
geneviewrs351855
scholarrs351855
googlers351855
pharmgkbrs351855
gwascentralrs351855
openSNPrs351855
23andMers351855
23andMe allrs351855
SNP Nexus

SNPshotrs351855
SNPdbers351855
MSV3drs351855
GeneFGFR4
Chromosome5
Orientationminus
GMAF0.303
Position176520243
ReferenceGRCh37 37.1/131
Max Magnitude2.8
Geno Mag Summary
(C;C) 0 normal
(C;T) 1.2 1.2x increased risk for prostate cancer
(T;T) 2.8 2x increased prostate cancer risk; among breast cancer patients, herceptin is less effective
? (C;C) (C;T) (T;T) 28
rs351855, a SNP in the fibroblast growth factor receptor 4 (FGFR4) gene, is also known as the Gly388Arg variant. The rs351855(T) allele encodes the risk (Arg) allele.

The Arg form of this SNP is likely to cause a harder to treat version of node-positive breast cancer, including reducing the efficacy of Herceptin, based on a study of 372 patients.[PMID 16822847]

A study of ~500 Japanese prostate cancer patients found that individuals with a rs351855(T;T) genotype had a 2.2- and 1.9-fold increased risk of prostate cancer and benign prostate hyperplasia (BPH), and a 1.8-fold increased risk of metastatic prostate cancer compared to the (C;C) genotype.[PMID 18756523]

A meta-analysis published in 2011, surveying a total of 2,618 cases of prostate cancer, concluded that the odds ratio per rs351855(T) allele was 1.17 (CI: 1.07 - 1.29), and that when stratified by race, Caucasians and Asians were at highest risk.[PMID 21349172OA-icon.png]

[PMID 18762813OA-icon.png] ~1500 prostate cancer patients showed only a weak association between rs351855 and prostate-cancer specific mortality, and no evidence associating it with prostate cancer risk, disease aggressiveness, Gleason score, or stage.

OMIM134935
DescCANCER PROGRESSION AND TUMOR CELL MOTILITY
Variant0001
Relatedalso



[PMID 21412156] Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor


[PMID 21656577] Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma


[PMID 22271411OA-icon.png] Pharmacogenetics of the Effects of Colesevelam on Colonic Transit in Irritable Bowel Syndrome with Diarrhea.


[PMID 22313031OA-icon.png] Fibroblast Growth Factor Receptor 4 Polymorphisms and Susceptibility to Coronary Artery Disease.


[PMID 22696188] Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study


ClinVar
Risk rs351855(T;T)
Alt rs351855(T;T)
Reference rs351855(C;C)
Significance 5
Disease Cancer progression and tumor cell motility
ClinVar info
Gene FGFR4
CLNDBN Cancer progression and tumor cell motility
Reversed 1
CLNHGVS NC_000005.9:g.176520243G>A
CLNSRC OMIM Allelic Variant
CLNACC RCV000017723.26



[PMID 19379518OA-icon.png] Development of a fingerprinting panel using medically relevant polymorphisms.


[PMID 19500394OA-icon.png] Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study.


[PMID 20565774OA-icon.png] Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.


[PMID 21396369OA-icon.png] A Klothobeta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.


GET Evidence
FGFR4-G388R
aa_change Gly388Arg
aa_change_short G388R
impact pharmacogenetic
qualified_impact Insufficiently evaluated pharmacogenetic
overall_frequency 0.24093
summary Possible association with sensitivity to cisplatin; poor outcome with cyclophosphamide, fluoruracil, methotextrate and tamoxifen.



[PMID 23206452] Association between Fibroblast Growth Factor Receptor 4 Gly388Arg Polymorphism and Ischaemic Stroke


[PMID 24381107] Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma


[PMID 23524567] FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer